Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
This phase I clinical trial is studying the side effects and best dose of giving
gamma-secretase inhibitor RO4929097 and cediranib maleate together in treating patients with
advanced solid tumors. Gamma-secretase inhibitor RO4929097 and cediranib maleate may stop the
growth of tumor cells by blocking some of the enzymes needed for cell growth. Cediranib
maleate also may stop the growth of tumor cells by blocking blood flow to the tumor.